What is ImmunityBio, Inc.'s EV / sales?

ImmunityBio, Inc. (IBRX) reported EV / sales of 57.9× in Q1 2026.

How has ImmunityBio, Inc.'s EV / sales changed year-over-year?

ImmunityBio, Inc.'s EV / sales decreased by 36.5% year-over-year, from 91.1× to 57.9×.

What is the long-term trend for ImmunityBio, Inc.'s EV / sales?

Over 5 years (2020 to 2025), ImmunityBio, Inc.'s EV / sales has grown at a -68.7% compound annual growth rate (CAGR), from 6,574.8× to 19.7×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

ImmunityBio, Inc. IBRX EV / sales

EV / sales at other companies

Bristol-Myers SquibbBMY

3.3×-0.1×

Johnson & JohnsonJNJ

6.5×+1.8×

Merck & Co.MRK

5.2×+1.2×

Gilead SciencesGILD

6.3×+0.9×

Kymera TherapeuticsKYMR

130.9×+101×

Summit TherapeuticsSMMT

8,448.1×+8,132×

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

enterprise value/total revenue=57.9×

Based on the most recent quarter.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s EV / sales?: ImmunityBio, Inc. (IBRX) reported EV / sales of 57.9× in Q1 2026.
How has ImmunityBio, Inc.'s EV / sales changed year-over-year?: ImmunityBio, Inc.'s EV / sales decreased by 36.5% year-over-year, from 91.1× to 57.9×.
What is the long-term trend for ImmunityBio, Inc.'s EV / sales?: Over 5 years (2020 to 2025), ImmunityBio, Inc.'s EV / sales has grown at a -68.7% compound annual growth rate (CAGR), from 6,574.8× to 19.7×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.